Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Evolutionary landscape of the mycobacterium tuberculosis complex from the viewpoint of phoPR: Implications for virulence regulation and application to vaccine development

  • Broset, E.
  • Martín, C.
  • Gonzalo-Asensio, J.
Different members of the Mycobacterium genus have evolved to cause tuberculosis in diverse human populations and in a variety of animal species. Our cumulative knowledge of mycobacterial genomes indicates that mutations in the PhoPR two-component virulence system were acquired not only during the natural evolution of mycobacterial species but also during in vitro subculture, which has given rise to the attenuated reference strain H37Ra or to different daughter strains of Mycobacterium bovis BCG. PhoPR is a well-known regulator of pathogenic phenotypes, including secretion of the virulence factor ESAT-6, biosynthesis of acyltrehalose-based lipids, and modulation of antigen export, in members of the Mycobacterium tuberculosis complex (MTBC)Evolutionarily conserved polymorphisms in PhoPR from Mycobacterium africanum, M. bovis, or M. tuberculosis H37Ra result in loss of functional phenotypes. Interestingly, some members of the MTBC have acquired compensatory mutations to counteract these polymorphisms and, probably, to maintain their pathogenic potential. Some of these compensatory mutations include the insertion of the IS6110 element upstream from phoPR in a particular M. bovis strain that is able to transmit between humans or polymorphisms in M. africanum and M. bovis that affect the regulatory region of the espACD operon, allowing PhoPR-independent ESAT-6 secretion. This review highlights the increasing knowledge of the significance of PhoPR in the evolution of the MTBC and its potential application in the construction of new attenuated vaccines based on phoPR inactivation. In this context, the live attenuated vaccine MTBVAC, based on a phoP fadD26 deletion mutant of M. tuberculosis, is the first vaccine of this kind to successfully enter into clinical development, representing a historic milestone in the field of human vaccinology.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: Results of a prospective phase 2 Spanish/PETHEMA trial

  • Mateos, M.V
  • Orio, A.
  • Rosiño, L.
  • Arriba, F.D.
  • Puig, N.
  • Martín, J.
  • Martínez-López, J.
  • Echeveste, M.A.
  • Sarrá, J.
  • Ocio, E.
  • Ramírez, G.
  • Martínez, R.
  • Palomera, L.
  • Payer, A.
  • Iglesias, R.
  • De Rubia, J.L.
  • Alegre, A.
  • Chinea, A.I.
  • Bladé, J.
  • Lahuerta, J.J.
  • Miguel, J.F S.
Bendamustine is a bifunctional alkylating agent with proven activity in myeloma. In this study 60 newly diag- nosed myeloma patients were given bendamustine plus bortezomib and prednisone in a regimen consisting of one cycle of bortezomib twice weekly for 6 weeks (1.3 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32), plus bendamus- tine (90 mg/m2 on days 1 and 4) and prednisone. The following cycles included bortezomib once weekly. Patients who were transplant candidates proceeded to stem cell collection after four cycles and the transplant was per- formed after six cycles. Patients who were not candidates for transplantation received up to nine cycles. Forty-two patients were transplant candidates and after six cycles, 50% achieved at least a very good partial response, with 24% having complete responses; 35 proceeded to a transplant, and the complete response rate was 54%. Seventeen patients continued up to nine cycles, and 57% achieved at least a very good partial response, including 26% with complete responses. The 2-year progression-free survival and overall survival rates were 62% and 86%, respectively. The safety profile was manageable, but stem cell mobilization was compromised in 35% of patients. In summary, this combination is effective in untreated patients, with an acceptable toxicity profile, but given the introduction of second-generation novel agents and monoclonal antibodies, the combination will probably be bet- ter reserved for relapsing patients, in whom stem cell collection is not needed, while cost-effective combinations with non-cross-resistant drugs continue to represent a medical need. This trial was registered with ClinicalTrials.gov, number NCT01376401.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Mycobacterium tuberculosis complex exhibits lineage-specific variations affecting protein ductility and epitope recognition

  • Yruela, Inmaculada
  • Contreras-Moreira, Bruno
  • Magalhães, Carlos
  • Osório, Nuno S.
  • Gonzalo-Asensio, Jesús
This work was supported by Gobierno de Aragón (DGA-GC B18 and B25), the Spanish Ministry of Science and Competitiveness (BIO2014-52580P, CSIC13-4E-2490), Instituto de Salud Carlos III (PI12/01970) and the European Commission Horizon 2020 (H2020-PHC-643381). Some of these grants were partially financed by the EU FEDER Program. This work was also supported by Fundação para a Ciência e Tecnologia, Portugal (IF/00474/2014) and cofunded by Programa Operacional Regional do Norte (ON.2—O Novo Norte), Quadro de Referência Estratégico Nacional (QREN), through the Fundo Europeu de Desenvolvimento Regional (FEDER).